How Sildenafil Citrate Works in the Body

Lonafarnib: (Major) Coadministration with

• The medication is classified as a controlled substance in some jurisdictions.
• Over-reliance on sildenafil without addressing underlying causes is discouraged.
• Psychological counseling may benefit some patients with ED.
• Detailed medical history helps determine if sildenafil is safe.
• Education on possible side effects improves patient safety.
• The drug does not cause dependency.
• Proper use ensures maximum therapeutic benefit and safety.

lonafarnib is not recommended

LinkOut - more resources

If these drugs are used together, closely monitor for signs of adverse events. Elexacaftor; tezacaftor; ivacaftor: (Moderate) Increased monitoring is recommended if ivacaftor is administered concurrently with CYP2C9 substrates, such as sildenafil. Ivacaftor is an inhibitor of CYP3A and a weak inhibitor of CYP2C9; sildenafil is metabolized by CYP3A and CYP2C9. Co-administration of ivacaftor with CYP3A and CYP2C9 substrates, such as sildenafil, can theoretically increase sildenafil exposure leading to increased or prolonged therapeutic effects and adverse events; however, the clinical impact of this has not yet been determined. Encorafenib: (Moderate) Coadministration of encorafenib with sildenafil may result in increased toxicity or decreased efficacy of sildenafil.

What should I do if I miss a dose of sildenafil?

In vitro studies with encorafenib showed time-dependent inhibition of CYP3A4 and induction of CYP3A4. The clinical relevance of the in vivo effect of encorafenib on CYP3A4 is not established. Enzalutamide: (Moderate) Monitor for decreased efficacy of sildenafil if coadministration with enzalutamide is necessary. Erythromycin: (Moderate) Monitor for an increase in sildenafil-related adverse reactions if coadministration with erythromycin is necessary; consider a starting dose of 25 mg of sildenafil when prescribed for erectile dysfunction. In a drug interaction study, coadministration with erythromycin increased the Cmax and AUC of sildenafil by 160% and 182%, respectively. in patients receiving sildenafil

for pulmonary arterial hypertension (PAH).